Compositions containing prodrugs of florfenicol and methods of use
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-037/12
A01N-037/44
A61K-031/24
A01N-037/02
A01K-031/22
C07C-069/66
출원번호
UP-0700069
(2007-01-31)
등록번호
US-7662861
(2010-04-03)
발명자
/ 주소
Murthy, Yerramilli V. S. N.
Suva, Robert H.
출원인 / 주소
IDEXX Laboratories, Inc.
대리인 / 주소
Townsend, Townsend & Crew
인용정보
피인용 횟수 :
0인용 특허 :
31
초록▼
The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one o
The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration.
대표청구항▼
The invention claimed is: 1. A method of treating a bacterial infection in a feline comprising injecting the feline with a composition comprising florfenicol butyrate and a pharmaceutically acceptable solvent wherein the composition is injected in a dose sufficient to provide an effective blood lev
The invention claimed is: 1. A method of treating a bacterial infection in a feline comprising injecting the feline with a composition comprising florfenicol butyrate and a pharmaceutically acceptable solvent wherein the composition is injected in a dose sufficient to provide an effective blood level of florfenicol. 2. The method of claim 1, wherein the pharmaceutically acceptable solvent is selected from the group consisting of pyrrolidone, N-methyl pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbid dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofufuryl alcohol, triacetin, and combinations thereof. 3. The method of claim 2, wherein the pharmaceutically acceptable solvent is selected from the group consisting of glycerol formal, propylene glycol, and mixtures thereof. 4. The method of claim 2, wherein the pharmaceutically acceptable solvent comprises about 90% glycerol formal and about 10% propylene glycol. 5. The method of claim 2, wherein the pharmaceutically acceptable solvent comprises N-methyl pyrrolidone. 6. The method of claim 1, wherein the florfenicol butyrate is present in an amount of about 10 to 60 percent (w/v) of the composition. 7. The method of claim 1, wherein the florfenicol butyrate is present in an amount of at least about 1 percent (w/v) of the composition. 8. The method of claim 1, wherein the florfenicol butyrate is present in an amount of at least about 5 percent (w/v) of the composition. 9. The method of claim 1, wherein the florfenicol butyrate is present in an amount of at least about 10 percent (w/v) of the composition. 10. The method of claim 1, wherein injecting the composition provides a drug depot in the mammal. 11. The method of claim 10, wherein the drug depot provides sustained release of the florfenicol butyrate. 12. The method of claim 11, wherein the drug depot provides extended release of the florfenicol butyrate to provide a pharmacologically acceptable serum level of florfenicol for between 1 and 15 days. 13. The method of claim 1, wherein the bacterial infection is a respiratory infection. 14. The method of claim 1, wherein the bacterial infection is caused by Escheri coli, Citrobacter, Proteus mirabilis, Proteus sp., Shigelia Salmonella, Providencia bacteroides, Staphylococcos aureus, Enterococci, Pasteurella haemolytica, Pasteurella muirocida, Heamophilus somnus, and Heamophilus influenza. 15. The method of claim 1, wherein the concentration of florfenicol butyrate in the composition is at least about 200 mg/mL. 16. The method of claim 15, wherein the concentration of florfenicol butyrate in the composition is at least about 300 mg/mL. 17. The method of claim 1, wherein the composition is injected at a dose of about 40 mg/kg. 18. A method of treating a bacterial infection in a feline comprising injecting the feline with a composition comprising florfenicol butyrate and a pharmaceutically acceptable solvent selected from the group consisting of glycerol formal, propylene glycol, and mixtures thereof, wherein the florfenicol butyrate is present in a concentration of at least about 250 mg/mL and wherein the composition is injected in a dose sufficient to provide an effective blood level of florfenicol. 19. The method of claim 18, wherein the pharmaceutically acceptable solvent comprises about 90% glycerol formal and about 10% propylene glycol. 20. The method of claim 19, wherein the composition is injected at a dose of about 40 mg/kg.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (31)
Nagabhushan Tattanahalli L. (Parsippany NJ), 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their manufacture and intermediates useful therein, methods.
Nagabhushan Tattanhalli L. (Parsippany NJ), 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful.
Nagabhushan Tattanahalli L. (Parsippany NJ), 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor.
Or Yat Sun ; Ma Zhenkun ; Clark Richard F. ; Chu Daniel T. ; Plattner Jacob J. ; Griesgraber George, 6-O-substituted ketolides having antibacterial activity.
Wu Guang-Zhong (Somerville NJ) Tormos Wanda I. (Elizabeth NJ), Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates.
Kohan, Raul E.; Varma, Kanwal J.; Simmons, Robert D.; Huq, Abu; Freehauf, Keith A., Compositions and method for treating infection in cattle and swine.
Camaggi Giovanni (Novara ITX) Chiarino Dario (Monza ITX) Fantucci Mario (Milan ITX) Meazza Giovanni (Saronno ITX), Compositions having herbicidal activity containing N-alkyl-amides as active ingredient.
Camaggi Giovanni (Novara ITX) Chiarino Dario (Monza ITX) Fantucci Mario (Milan ITX) Meazza Giovanni (Saronno ITX), Compositions having herbicidal activity containing N-alkyl-amides as active ingredient.
Schumacher Doris P. (Floraham Park NJ) Clark Jon E. (Highland Park NJ) Murphy Bruce L. (Glen Ridge NJ), Pressurized fluorination of hydroxy alkyl groups.
Jommi Giancarlo (Milan ITX) Chiarino Dario (Monza ITX) Pagliarin Roberto (San Giorgio Su Legnano ITX), Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds.
Clark Jon E. (Highland Park NJ) Schumacher Doris P. (Florham Park NJ) Wu Guang-Zhong (Somerville NJ), Process for preparing florfenicol, its analogs and oxazoline intermediates thereto.
May Thomas ; Hofstetter John ; Olson Kathleen L. ; Menon Sukumaran K. ; Mikrut Bernard A. ; Ovenshire Clayton S. ; Rhodes Lawrence John ; Speicher Earl R. ; Waterson James R., Propofol composition.
Schoenleber Robert W. (Deerfield IL) Ehrlich Paul P. (Evanston IL) Kebabian John W. (Lake Bluff IL) Campbell James R. (Ft. Sheridan IL), Tetracyclic spirobenzazepine dopamine antagonists.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.